tbuckley/cabot-search huggingface dataset:
STUCCO KERATOSIS
Authors: OLIVER SCOTT, JOANNA WARD
Journal: British Journal of Dermatology (1971)

Journal Article STUCCO KERATOSIS Get access OLIVER SCOTT, OLIVER SCOTT Department of Dermatology, Charing Crow Hospital and Medical School, London, W.C.2 Search for other works by this author on: Oxford Academic Google Scholar JOANNA WARD JOANNA WARD Department of Dermatology, Charing Crow Hospital and Medical School, London, W.C.2 Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 84, Issue 4, 1 April 1971, Pages 376–379, https://doi.org/10.1111/j.1365-2133.1971.tb14236.x Published: 01 April 1971 Article history Accepted: 20 November 1970 Published: 01 April 1971
Illnesses and Injuries Related to Total Release Foggers—Eight States, 2001-2006
Journal: JAMA (2008)

Total release foggers (TRFs), sometimes called "bug bombs," are pesticide products designed to fill an area with insecticide and often are used in homes and workplaces to kill cockroaches, fleas, and flying insects. Most TRFs contain pyrethroid, pyrethrin, or both as active ingredients. TRFs also contain flammable aerosol propellants that can cause fires or explosions. The magnitude and range of acute health problems associated with TRF usage has not been described previously. This report summarizes illnesses and injuries that were associated with exposures to TRFs during 2001--2006 in eight states (California, Florida, Louisiana, Michigan, New York, Oregon, Texas, and Washington) and were investigated by the California Department of Pesticide Regulation (CDPR) and state health departments participating in the SENSOR-Pesticides program. During 2001-2006, a total of 466 TRF-related illnesses or injuries were identified. These illnesses or injuries often resulted from inability or failure to vacate before the TRF discharged, reentry into the treated space too soon after the TRF was discharged, excessive use of TRFs for the space being treated, and failure to notify others nearby. The findings indicate that TRFs pose a risk for acute, usually temporary health effects among users and bystanders. To reduce the risk for TRF-related health effects, integrated pest management control strategies that prevent pests' access to food, water, and shelter need to be promoted and adopted. In addition, awareness of the hazards and proper use of TRFs need to be better communicated on TRF labels and in public media campaigns.
The investigation of sinusitis.
Journal: BMJ (1980)

The investigation of sinusitis Inflammation of the paranasal sinuses is a common and important cause of morbidity, though it rarely threatens life.Statistics produced by the Department of Health and Social Security' estimate that half a million working days are lost in Britain each year from this cause.Acute inflammation most commonly affects the maxillary sinus and is less common in the ethmoid, frontal, and sphenoid sinuses, but more than one may be inflamed simultaneously.The initial infection of the nasal sinus is often viral in origin, with secondary bacterial invasion; the usual cause is the acute rhinitis associated with the common cold, but pharyngeal infections may also spread to these regions.Most patients with acute sinusitis are treated by their general practitioners, and referral to an ear, nose, and throat surgeon is required only if complications develop.Chronic sinusitis, less common today than in the past, usually requires investigation and treatment by the rhinologist since it responds less readily to treatment with antibiotics; antral lavage will often be required and occasionally surgery, such as the Caldwell-Luc operation.Acute sinusitis requires treatment with an appropriate antibiotic, decongestive nasal drugs, analgesics, and local heat.Most patients respond rapidly to this regimen.If possible the organisms responsible for the infection should be identified so that the right antibiotic can be chosen and given for long enough to eradicate the infection; recurrence is common if the course of treatment is too short.Specimens may be taken from the nose for culture, sensi- tivity tests, and cytological examination using swabs from the nasal vestibule or the posterior nares or by a proof puncture of the maxillary sinus.The first two methods are rarely satisfactory because of contamination with other organismsin at least one-fifth of the population a staphylococcus will be cultured which may or may not be related to the organisms
Highlights
Journal: JAMA (2015)

Life Expectancy in Patients With Type 1 Diabetes 37Historically, type 1 diabetes mellitus has been associated with large reductions in life expectancy.Livingstone and colleagues assessed life expectancy in a contemporary cohort of 24 691 Scottish patients with type 1 diabetes and found that compared with the general population, subsequent life expectancy at age 20 years for patients with diabetes was approximately 11 years less for men and 13 years less for women.In an Editorial, Katz and Laffel discuss prevention of diabetes complications to improve patient survival.
Genetic instability and darwinian selection in tumours
Authors: Daniel P Cahill, Kenneth W Kinzler, Bert Vogelstein, Christoph Lengauer
Journal: Trends in Genetics (1999)

Genetic instability has long been hypothesized to be a cardinal feature of cancer. Recent work has strengthened the proposal that mutational alterations conferring instability occur early during tumour formation. The ensuing genetic instability drives tumour progression by generating mutations in oncogenes and tumour-suppressor genes. These mutant genes provide cancer cells with a selective growth advantage, thereby leading to the clonal outgrowth of a tumour. Here, we discuss the role of genetic instability in tumour formation and outline future work necessary to substantiate the genetic instability hypothesis.
AMA-RPS Chooses Chairperson-Elect
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Classic Cardiology
Authors: Gilbert F. Mudge
Journal: JAMA (1997)

<b>Classic Teachings in Clinical Cardiology: A Tribute to W. Proctor Harvey</b>, vols 1 &amp; 2, edited by Michael A. Chizner, 1526 pp, with illus, $145, ISBN 1-886128-06-5, Cedar Grove, NJ, Laennec Publishing, 1996. The cardiology community is fortunate to have access to encyclopedic texts that undergo frequent and timely revision and are now integrated with the most advanced information technology. A request to review<i>Classic Teaching in Clinical Cardiology</i>evoked some initial skepticism that another 1500-page, two-volume edition would have a meaningful place in the library of the cardiovascular specialist. Such skepticism was clearly premature and not justified. Former students and cardiology fellows of W. Proctor Harvey, MD, have compiled a 62-chapter book that details the subspecialty from the perspective of clinical skills and evaluations and honors Dr Harvey's unique contribution to cardiology. The work's consistent emphasis on the clinical art of cardiovascular medicine is its lasting contribution. The first
Computed tomography: bigger and better?
Journal: JAMA (1979)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Book: Addicted
Authors: M. Farrell
Journal: BMJ (1999)

Tony Adams, Ian Ridley Collins Willow, £16.99, pp 288 ISBN 0 00218794 9 ——————— Rating: ![Graphic][1]</img>![Graphic][2]</img>![Graphic][3]</img> Raymond Carver was one of the most elegant and lyrical writers about alcoholism and its corrosion of the human spirit. His solid evocation of ordinary life in recovery is inspirational. His gritty body of work, produced in the years before he died prematurely of cancer, is a gift to the world grabbed from the throes of self destruction. The same cannot be said of much of the torrent of self confessional autobiographies that have sprung from the recovery movement and … [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif [3]: /embed/inline-graphic-3.gif
Back Cover Image, Volume 40, Issue 2
Authors: Xing Chen, Wen‐Jian Tang, Jing Bo Shi, Ming Ming Liu, Xin‐Hua Liu
Journal: Medicinal Research Reviews (2020)

Description of the back cover image: The cover image is based on the REVIEW ARTICLE Therapeutic strategies for targeting telomerase in cancer by Xing Chen et al., https://doi.org/10.1002/med.21626. Credit: Cover image © Xing Chen.
Suppose There Were No Printers
Authors: Frank Davidoff
Journal: Annals of Internal Medicine (2001)

Letters20 February 2001Suppose There Were No PrintersFrank Davidoff, MDFrank Davidoff, MDEditor (Davidoff)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-134-4-200102200-00024 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:As I pointed out in an earlier editorial (1). I agree with Dr. Walker that print and digital media each have important advantages. I also agree that physicians and others who work in health care are not exempt from reading disabilities, and might be helped by the kinds of electronic cognitive assistance he describes. Unfortunately, few medical Web sites (including ours) have actually developed such “assistive technologies,” although the opportunity is clearly there (1). Dr. Walker's comments are generally very much on target, but they really don't get at my concerns about the shortcomings of electronic media, which ...Reference1. Davidoff F. www.annals.org [Editorial]. Ann Intern Med. 2000; 132:92. [PMID: 0010627259] Google Scholar Author, Article, and Disclosure InformationAffiliations: Editor (Davidoff) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee Alsowww.annals.org Frank Davidoff Suppose There Were No Printers Frank Davidoff Suppose There Were No Printers Randall Walker Metrics 20 February 2001Volume 134, Issue 4Page: 343KeywordsDisabilitiesHealth care ePublished: 20 February 2001 Issue Published: 20 February 2001 CopyrightCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Value of Positron Emission Tomography With [F-18]Fluorodeoxyglucose in Patients With Colorectal Liver Metastases: A Prospective Study
Authors: T.J.M. Ruers, B.S. Langenhoff, N. Neeleman, G. J. Jager, S. Strijk, Th. Wobbes, F. H.M. Corstens, W. J.G. Oyen
Journal: Journal of Clinical Oncology (2002)

To assess prospectively the value of fluor-18-deoxyglucose (FDG) positron emission tomography (PET), in addition to conventional diagnostic methods (CDM), as a staging modality in candidates for resection of colorectal liver metastases.In 51 patients analyzed for resection of colorectal liver metastases, clinical management decisions were recorded after a complete work-up with CDM. Afterward, FDG-PET scans were performed and any change of clinical management according to FDG-PET results was carefully documented. Discordances between FDG-PET and CDM results were identified and related to the final diagnosis by histopathology, intraoperative findings, and follow-up.In 10 (20%) out of 51 patients, clinical management decisions based on CDM were changed after FDG-PET findings were known. FDG-PET detected unresectable pulmonary (n = 5) and hepatic metastases (n = 1) and ruled out extrahepatic (n = 2) and hepatic disease (n = 2). Due to FDG-PET, eight patients were spared unwarranted liver resection or laparotomy and two other patients were identified as candidates for liver resection. When the results of FDG-PET were regarded as decisive in a retrospective analysis, potential change of management was 29% (15 patients). FDG-PET and CDM showed discordant extrahepatic results in 11 patients (22%) and discordant hepatic results in eight patients (16%). Compared with CDM, FDG-PET resulted in true upstaging (n = 11), true downstaging (n = 5), false upstaging (n = 1), and false downstaging (n = 2). The detection rate of liver metastases on a lesion basis was generally better for computed tomography than for FDG-PET (80% v 65%); this was related to tumor size.FDG-PET as a complementary staging method improves the therapeutic management of patients with colorectal liver metastases, especially by detecting unsuspected extrahepatic disease.
OC-028 Statin use is Associated with Improved Survival in Patients with Oesophageal Cancer: a Survival Analysis using the UK General Practice Research Database and National Cancer Registry
Authors: L Alexandre, A Clark, H Bhutta, M P Lewis, S Holt, A R Hart
Journal: Gut (2013)

<h3>Introduction</h3> Patients with oesophageal cancer (OC) commonly present with an advanced stage of disease, and are often only amenable to palliative therapies. Of the minority suitable for potentially curative surgery, up to 50% develop recurrence at one year. Statins demonstrate several anticarcinogenic properties in oesophageal adenocarcinoma (OAC) cell lines including reducing cell proliferation, stimulating apoptosis and potentially limiting metastatic potential. We investigated for the first time the hypothesis that statin use after diagnosis or post-oesophagectomy was associated with improved survival in patients with OC. <h3>Methods</h3> Cases of OC diagnosed between 1st January 2000 and 31st December 2009 were identified from the UK General Practice Research Database (GPRD). The GPRD data was linked to the UK National Cancer Registry (NCR) to determine histological subtype. Cox proportional hazard regression analysis with time-dependent exposures, estimated the associations between statin use (versus non-users) from diagnosis and post-surgery on overall survival and disease-specific survival. Multivariate analyses were adjusted for age, gender, body mass index, diabetes mellitus, cardiovascular disease, oesophagectomy, chemotherapy, radiotherapy and ACE inhibitor use. <h3>Results</h3> In total 4445 cases of OC were identified, of which 606 were OAC and 344 were OSCC (histology data was available for 21.4% of patients). Overall 585 (13.2%) patients underwent oesophagectomy. In total 609 (13.7%) of patients were statin users following diagnosis and 109 (19.2%) following surgery. There were improved survival times following diagnosis for patients prescribed a statin with OC overall (HR = 0.71, 95% CI = 0.64–0.79, p &lt; 0.001) and specifically OAC (HR = 0.58, 95% CI = 0.43–0.78, p &lt; 0.001). Furthermore, statin use post-oesophagectomy was associated with improved survival in those with OC overall (HR = 0.66, 95% CI = 0.48–0.91, p = 0.013) and those with OAC specifically (HR = 0.58, 95% CI = 0.30–1.10, p = 0.096) with borderline significance. There were no significant effects between statin use and survival in patients with OSCC. Associations between statin use and overall survival were very similar to their effect on disease-specific survival. <h3>Conclusion</h3> Statin use in patients with OC either after diagnosis or post-oesophagectomy is associated with improved survival. This data suggests a need for randomised controlled trials of statins in patients with OC. <h3>Disclosure of Interest</h3> None Declared
Vaccine Model
Authors: Rebecca Voelker
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction
Journal: BMJ (1944)

to the con- junctiva, or the subcutaneous njection of paraphenylendiamine, was demonstrated by L. T. Poulsson (Arch.exp.Pathol.Pliarmakol., 1927, 120, 120).The after-pain can be dealt with only by the usual analgesics such as aspirin, pethidine, or morphine.
Hispanic accrual on randomized cancer clinical trials: A call to arms.
Authors: Alberto Parra, Anand B. Karnad, Ian Murchie Thompson
Journal: Journal of Clinical Oncology (2014)

e17555 Background: While health disparities and therapy outcomes within different racial and ethnic populations has been studied, data on Hispanics is sparse. In an effort to provide care and a benchmark for accrual efforts to our predominately Hispanic population, the Cancer Therapy and Research Center (CTRC), a National Cancer Institute-designated Cancer Center in San Antonio, Texas, explored rates of Hispanic patient participation in prevention and clinical trials. Methods: A search of all phase II and III cancer clinical trials published in the 2012 calendar year or led by clinical investigators in the United States focusing on minority accrual in the following journals: New England Journal of Medicine, Journal of Clinical Oncology, Journal of the National Cancer Institute, Lancet, and Blood. Results: Of the 159 phase II and III clinical trials in 2012, 33 articles (20.75%) reported rates of minority accrual and 13 articles (8.18%) reported Hispanic accrual rates. Accrual within these 13 articles ranged from 1 patient (0.5%) to 17 patients (26%). Overall, Hispanic accrual was 3.9%, as estimated from the accrual of 162 Hispanics out of total 4,154 patients reported in 13 trials. Conclusions: While the CTRC has innovative programs to accrue minorities, continued efforts to improve accrual and reporting rates of Hispanics in clinical trials need to be taken to better treat this growing U.S population. Cancer clinical trials with reports of minority accrual in 2012. Author/journal/reference Trial phase Total accrual Hispanic accrual – number of patients (percent) O'Brien S, et al, J Clin Oncol 31:676 2 65 17 (26%) Levine AM, et al, J Clin Oncol 31:58 2 40 10 (25%) Kindler HL, et al, J Clin Oncol 30:2509 2 115 6 (5.22) Lynch TJ, et al, J Clin Oncol 30:2046 2 204 1 (0.5%) Tap WD, et al, J Clin Oncol 30:1849 2 38 6 (16%) Uldrick TS, et al, J Clin Oncol 30:1476 2 17 3 (17.64%) Sosman JA, et al, N Engl J Med 366:707 2 132 2 (2%) Karlan BY, et al, J Clin Oncol 30:362 2 161 5 (3.10%) Cruciani RA, et al, J Clin Oncol 30:3864 3 376 5 (1.32%) Paz-Ares LG, et al, J Clin Oncol 30:3084 3 772 16 (2.07%) Scagliotti GV, et al, J Clin Oncol 30:2829 3 1,090 66 (6.05%) Levenback CF, et al, J Clin Oncol 30:3786 3 452 9 (2%) Socinski MA, et al, J Clin Oncol 30:2055 3 1,052 16 (2%) Grand total 4,154 162 (3.9%)
Characterization of the antiviral effects of 2′ carbodeoxyguanosine in ducks chronically infected with duck hepatitis B virus
Authors: W Mason
Journal: Hepatology (1994)

This study was carried out to evaluate benefits and limitations of long-term therapy of hepatitis B virus infections with a nucleoside analog inhibitor of virus replication. The model we used was the domestic duck chronically infected with duck hepatitis B virus by in ovo infection. 2′ Carbodeoxyguanosine was used as an inhibitor of viral DNA synthesis. In all animals examined there was a reduction in virus production during therapy. A dose of 2′ carbodeoxyguanosine of 10 μg/kg every other day reduced the number of infected hepatocytes from greater than 95 to 25 to 50 in less than 3 mo, whereas a 10-fold higher dose produced a decline to less than 10. Histological evaluation revealed mild to moderate liver injury in ducks receiving the higher dose of 2′ carbodeoxyguanosine, suggesting that disappearance of infected hepatocytes may have been accelerated by a toxic effect of the drug. Drug treatment did not completely eliminate duck hepatitis B virus from any duck, and replication was restored in all hepatocytes within a few weeks to several months after antiviral therapy was terminated. Our results suggest that elimination of a chronic infection with a single inhibitor of replication may be difficult in a host that lacks an antiviral immune response capable of eliminating at least a portion of the infected hepatocytes and of ultimately producing antibodies capable of neutralizing residual virus. (Hepatology 1994; 19:398–411).